Verona Pharma plc (NASDAQ:TARA) major shareholder Randall Marshall sold 2,516 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $26.42, for a total transaction of $66,472.72. Following the sale, the insider now directly owns 613,197 shares in the company, valued at approximately $16,200,664.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Randall Marshall also recently made the following trade(s):

  • On Monday, July 27th, Randall Marshall sold 338 shares of Verona Pharma stock. The stock was sold at an average price of $26.08, for a total transaction of $8,815.04.
  • On Friday, July 24th, Randall Marshall sold 2,343 shares of Verona Pharma stock. The stock was sold at an average price of $26.53, for a total transaction of $62,159.79.
  • On Wednesday, July 22nd, Randall Marshall sold 1,372 shares of Verona Pharma stock. The stock was sold at an average price of $26.73, for a total transaction of $36,673.56.
  • On Friday, July 17th, Randall Marshall sold 1,601 shares of Verona Pharma stock. The shares were sold at an average price of $26.66, for a total transaction of $42,682.66.
  • On Monday, July 20th, Randall Marshall sold 4,330 shares of Verona Pharma stock. The shares were sold at an average price of $26.79, for a total transaction of $116,000.70.
  • On Monday, July 13th, Randall Marshall sold 2,145 shares of Verona Pharma stock. The shares were sold at an average price of $27.13, for a total transaction of $58,193.85.
  • On Friday, July 10th, Randall Marshall sold 2,659 shares of Verona Pharma stock. The shares were sold at an average price of $27.41, for a total transaction of $72,883.19.

TARA opened at $24.94 on Friday. The company has a fifty day moving average price of $28.93. Verona Pharma plc has a 1 year low of $8.80 and a 1 year high of $67.08.

Verona Pharma (NASDAQ:TARA) last posted its earnings results on Wednesday, May 13th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($1.40). Research analysts anticipate that Verona Pharma plc will post -2.59 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. acquired a new position in Verona Pharma during the fourth quarter worth $32,000. Citigroup Inc. purchased a new stake in shares of Verona Pharma in the first quarter valued at about $43,000. DRW Securities LLC purchased a new stake in shares of Verona Pharma in the first quarter valued at about $3,071,000. Ikarian Capital LLC purchased a new stake in shares of Verona Pharma in the first quarter valued at about $10,368,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Verona Pharma in the first quarter valued at about $184,000. Hedge funds and other institutional investors own 67.70% of the company’s stock.

Several research firms have recently commented on TARA. Zacks Investment Research raised shares of Verona Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, July 15th. Guggenheim began coverage on shares of Verona Pharma in a report on Wednesday. They issued a “buy” rating and a $50.00 price objective on the stock.

About Verona Pharma

ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

Further Reading: Understanding Options Trading

Insider Buying and Selling by Quarter for Verona Pharma (NASDAQ:TARA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.